Sickle cell disease and venous thromboembolism: What the anticoagulation expert needs to know

Research output: Contribution to journalArticlepeer-review

Abstract

Venous thromboembolism (VTE) is common in patients with sickle cell disease (SCD). The etiology of increased risk of VTE in SCD patients is multifactorial and is related to both traditional factors and SCD-specific factors. Traditional risk factors such as central venous catheters, frequent hospitalization, orthopedic surgeries for avascular necrosis, and pregnancy may lead to increased incidence of VTE in the SCD population. In addition, SCD itself appears to be a hypercoagulable state, and many SCD-specific factors such as thrombophilic defects, genotype and splenectomy may modify the risk of VTE. SCD complications such as acute chest syndrome and pulmonary hypertension may also be related to VTE. Anticoagulation experts should be aware of these factors to help inform prophylaxis and treatment decisions.

Original languageEnglish (US)
Pages (from-to)352-358
Number of pages7
JournalJournal of Thrombosis and Thrombolysis
Volume35
Issue number3
DOIs
StatePublished - Apr 1 2013

Keywords

  • Anticoagulation
  • Deep venous thrombosis
  • Pulmonary embolism
  • Sickle cell disease
  • Venous thromboembolism

ASJC Scopus subject areas

  • Hematology
  • Cardiology and Cardiovascular Medicine

Fingerprint Dive into the research topics of 'Sickle cell disease and venous thromboembolism: What the anticoagulation expert needs to know'. Together they form a unique fingerprint.

Cite this